Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: A systematic review

Neuro-Oncology

Volumn 17, Issue 7, 2015, Pages 924-934

  Koekkoek, Johan A F ^a,b   Kerkhof, Melissa ^b   Dirven, Linda ^a   Heimans, Jan J ^a   Reijneveld, Jaap C ^a   Taphoorn, Martin J B ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

chemotherapy; epilepsy; glioma; radiotherapy; review

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FOTEMUSTINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; GAMMA KNIFE RADIOSURGERY; GLIOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEIZURE; STEREOTACTIC RADIOSURGERY; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN NEOPLASMS; COMPLICATION; SEIZURES;

BRAIN NEOPLASMS; GLIOMA; HUMANS; SEIZURES; TREATMENT OUTCOME;

EID: 84936770771     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov032     Document Type: Review

References (68)

1. Danfors T, Ribom D, Berntsson SG, et al. Epileptic seizures and survival in early disease of grade 2 gliomas. Eur J Neurol. 2009; 16(7):823-831.
2. Weller M, Stupp R, WickW. Epilepsy meets cancer: When, why, and what to do about it? Lancet Oncol. 2012;13(9):e375-e382.
3. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia. 2013;54(Suppl 9):12-17.
4. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15(4):1294-1301.
5. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery. 1996;38(5):872-878.
6. You G, Sha ZY, Yan W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: A clinicopathological study. Neuro Oncol. 2012;14(2):230-241.
7. Smits A, Duffau H. Seizures and the natural history ofWorld Health Organization grade II gliomas: A review. Neurosurgery. 2011;68(5): 1326-1333.
8. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: The impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514-520.
9. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3(3):159-168.
10. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-430.
11. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108(2):227-235.
12. Sherman JH, Moldovan K, Yeoh HK, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114(6):1617-1621.
13. Ruda R, Magliola U, Bertero L, et al. Seizure control following radiotherapy in patients with diffuse gliomas: A retrospective study. Neuro Oncol. 2013;15(12):1739-1749.
14. Kahlenberg CA, Fadul CE, Roberts DW, et al. Seizure prognosis of patients with low-grade tumors. Seizure. 2012;21(7):540-545.
15. Quigg M, Barbaro NM. Stereotactic radiosurgery for treatment of epilepsy. Arch Neurol. 2008;65(2):177-183.
16. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
17. van den Bent MJ, Wefel JS, Schiff D, et al. Response Assessment in Neuro-Oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583-593.
18. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61(5):484-490.
19. Butowski N, Chang SM. Endpoints for clinical trials and revised assessment in neuro-oncology. Curr Opin Neurol. 2012;25(6): 780-785.
20. Viaccoz A, Lekoubou A, Ducray F. Chemotherapy in low-grade gliomas. Curr Opin Oncol. 2012;24(6):694-701.
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.
22. Mason WP, Krol GS, Deangelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46(1):203-207.
23. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68(21):1831-1836.
24. Tosoni A, Franceschi E, Ermani M, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol. 2008; 89(2):179-185.
25. Plathow C, Schulz-Ertner D, Thilman C, et al. Fractionated stereotactic radiotherapy in low-grade astrocytomas: Long-term outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003;57(4):996-1003.
26. Shankar A, Rajshekhar V. Radiological and clinical outcome following stereotactic biopsy and radiotherapy for low-grade insular astrocytomas. Neurol India. 2003;51(4):503-506.
27. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43(8): 1599-1601.
28. Rossi GF, Scerrati M, Roselli R. Epileptogenic cerebral low-grade tumors: Effect of interstitial stereotactic irradiation on seizures. Appl Neurophysiol. 1985;48(1-6):127-132.
29. Schrö ttner O, Eder HG, Unger F, et al. Radiosurgery in lesional epilepsy: Brain tumors. Stereotact Funct Neurosurg. 1998; 70(Suppl 1):50-56.
30. Schröttner O, Unger F, Eder HG, et al. Gamma-knife radiosurgery of mesiotemporal tumour epilepsy observations and long-term results. Acta Neurochir Suppl. 2002;84:49-55.
31. Scerrati M, Montemaggi P, Iacoangeli M, et al. Interstitial brachytherapy for low-grade cerebral gliomas: Analysis of results in a series of 36 cases. Acta Neurochir (Wien). 1994; 131(1-2):97-105.
32. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990.
33. Warnke PC, Berlis A, Weyerbrock A, et al. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. Acta Neurochir Suppl. 1997;68:90-92.
34. Biemond-ter Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer. 2005;103(4):802-809.
35. Blonski M, Taillandier L, Herbet G, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: A study of cognitive status and quality of life. J Neurooncol. 2012;106(2):353-366.
36. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715-1721.
37. Frenay MP, Fontaine D, Vandenbos F, et al. First-line nitrosoureabased chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol. 2005;12(9):685-690.
38. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133-3138.
39. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007;14(4):391-398.
40. Koekkoek JA, Dirven L, Heimans JJ, et al. Seizure reduction in a low-grade glioma: More than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry. 2014; doi: 10.1136/jnnp-2014-308136.
41. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722-1726.
42. Soffietti R, Ruda R, Bradac GB, et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43(5):1066-1073.
43. Taillandier L, Duffau H. Epilepsy and insular Grade II gliomas: An interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus. 2009;27(2):E8.
44. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
45. Luyken C, Blumcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: Long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia. 2003;44(6): 822-830.
46. Chaichana KL, Parker SL, Olivi A, et al. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg. 2009;111(2):282-292.
47. Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137(Pt 2):449-462.
48. Birbeck GL, Hays RD, Cui X, et al. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia. 2002;43(5): 535-538.
49. McLachlan RS, Rose KJ, Derry PA, et al. Health-related quality of life and seizure control in temporal lobe epilepsy. Ann Neurol. 1997; 41(4):482-489.
50. Khan RB, Onar A. Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors. Epilepsia. 2006;47(2):375-379.
51. Das RR, Artsy E, Hurwitz S, et al. Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol. 2012;107(3):565-570.
52. Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: New insights and evidence-based management. Oncologist. 2014;19(7):751-759.
53. Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol. 2003;30(6 Suppl 9):45-48.
54. Koekkoek JA, Kerkhof M, Dirven L, et al. Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: Design of a prospective observational study. BMC Neurol. 2014;14:157.
55. Pallud J, Llitjos JF, Dhermain F, et al. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2012;14(4):496-505.
56. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: A lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12(10):1078-1082.
57. Rosati A, Buttolo L, Stefini R, et al. Efficacy and safety of levetiracetam in patients with glioma: A clinical prospective study. Arch Neurol. 2010;67(3):343-346.
58. Alexander E III, Loeffler JS. Radiosurgery for primary malignant brain tumors. Semin Surg Oncol. 1998;14(1):43-52.
59. Della PA, Denaro L, Rossetto M, et al. Postoperative seizure in high grade glioma patients treated with BCNU wafers. A monoinstitutional experience. J Neurooncol. 2011;105(2):275-280.
60. Waters JD, Rose B, Gonda DD, et al. Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. J Neurooncol. 2013;113(3):467-477.
61. Shrieve DC, Alexander E III, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36(2): 275-282.
62. Chin LS, Lazio BE, Biggins T, et al. Acute complications following gamma knife radiosurgery are rare. Surg Neurol. 2000;53(5): 498-502.
63. Hu A, Xu Z, Kim RY, et al. Seizure control: A secondary benefit of chemotherapeutic temozolomide in brain cancer patients. Epilepsy Res. 2011;95(3):270-272.
64. Ruda R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol. 2010;22(6):611-620.
65. de Groot M, Reijneveld JC, Aronica E, et al. Epilepsy in patients with a brain tumour: Focal epilepsy requires focused treatment. Brain. 2012;135(Pt 4):1002-1016.
66. Ciceroni C, Bonelli M, Mastrantoni E, et al. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ. 2013;20(3):396-407.
67. Litterman AJ, Zellmer DM, Grinnen KL, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013;190(12):6259-6268.
68. Shamji MF, Fric-Shamji EC, Benoit BG. Brain tumors and epilepsy: Pathophysiology of peritumoral changes. Neurosurg Rev. 2009; 32(3):275-284.